Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Convertible Debt (2024 - 2026)

Alto Neuroscience has reported Convertible Debt over the past 3 years, most recently at $2.3 million for Q1 2026.

  • Quarterly results put Convertible Debt at $2.3 million for Q1 2026, up 92.82% from a year ago — trailing twelve months through Mar 2026 was $2.3 million (up 92.82% YoY), and the annual figure for FY2025 was $2.2 million, up 70.78%.
  • Convertible Debt reached $2.3 million in Q1 2026 per ANRO's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $2.3 million in Q1 2026 and bottomed at $1.2 million in Q1 2025.
  • Median Convertible Debt over the past 3 years was $2.0 million (2025), compared with a mean of $1.8 million.
  • The largest annual shift saw Convertible Debt soared 63.64% in 2025 before it surged 92.82% in 2026.
  • Over 3 years, Convertible Debt stood at $1.3 million in 2024, then soared by 70.78% to $2.2 million in 2025, then grew by 4.85% to $2.3 million in 2026.
  • Business Quant data shows Convertible Debt for ANRO at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $2.1 million in Q3 2025.